Deep understanding of the genomic and immunological differences between Chinese and
Western lung cancer patients is of great importance for target therapy selection and …

Immunotherapy is a currently popular treatment strategy for cancer patients. Although recent
developments in cancer immunotherapy have had significant clinical impact, only a subset …

In the past 10 years, a deeper understanding of the immune landscape of cancers, including
immune evasion processes, has allowed the development of a new class of agents. The …

BACKGROUND. The PD-1–blocking antibody nivolumab persists in patients several weeks
after the last infusion. However, no study has systematically evaluated the maximum …

Introduction KRAS mutation is the most frequent molecular alteration found in advanced
NSCLC; it is associated with a poor prognosis without available targeted therapy. Treatment …

Despite substantial progress in lung cancer immunotherapy, the overall response rate in
patients with KRAS-mutant lung adenocarcinoma (LUAD) remains low. Combining standard …

Monocytes influence multiple aspects of tumor progression, including antitumor immunity,
angiogenesis, and metastasis, primarily by infiltrating tumors, and differentiating into tumor …

Over the past decade, RAS oncogenic proteins have transitioned from being deemed
undruggable to having two clinically approved drugs, with several more in advanced stages …

Summary KRAS G12C inhibitors (adagrasib and sotorasib) have shown clinical promise in
targeting KRAS G12C-mutated lung cancers; however, most patients eventually develop …

For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable
molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L) 1 …